

REVIEW

Open Access

Pharmacological treatment of delayed cerebral ischemia and vasospasm in subarachnoid hemorrhage

Diego Castanares-Zapatero and Philippe Hantson*

Abstract

Subarachnoid hemorrhage after the rupture of a cerebral aneurysm is the cause of 6% to 8% of all cerebrovascular accidents involving 10 of 100,000 people each year. Despite effective treatment of the aneurysm, delayed cerebral ischemia (DCI) is observed in 30% of patients, with a peak on the tenth day, resulting in significant infirmity and mortality. Cerebral vasospasm occurs in more than half of all patients and is recognized as the main cause of delayed cerebral ischemia after subarachnoid hemorrhage. Its treatment comprises hemodynamic management and endovascular procedures. To date, the only drug shown to be efficacious on both the incidence of vasospasm and poor outcome is nimodipine. Given its modest effects, new pharmacological treatments are being developed to prevent and treat DCI. We review the different drugs currently being tested.

Introduction

Delayed cerebral ischemia (DCI) is a common and serious complication following subarachnoid hemorrhage (SAH) after ruptured cerebral aneurysmal [1,2]. Although this complication is at times reversible, it may develop into a cerebral infarction [3]. DCI occurs in approximately 20% to 40% [4] of patients and is associated with increased mortality and poor prognosis [5,6]. It is usually caused by a vasospasm [7], which, although preventable, remains a major cause of poor neurological outcome and increased mortality in the course of SAH [4-6].

Vasospasm is defined as a reversible narrowing of the subarachnoid arteries occurring between the third to fifth and fifteenth day after the hemorrhage, with a peak at the tenth day. It is observed in 70% of patients on angiographic scans and causes symptoms in 50% [7-10]. Angiographic vasospasm is defined as evidence of arterial narrowing compared with the parent vessels [11]. It preferentially involves the vessels of the cranial base but also may affect small-caliber vessels or diffusely the entire cerebral vascularization. The severity of vasospasm is variable. The subsequent decrease in cerebral

blood flow (CBF) in the spastic arteries leads to DCI, which may develop into cerebral infarction [7,12,13].

The etiology of vasospasm is complex and still poorly understood. Several factors have been shown to be involved, such as endothelial dysfunction, loss of autoregulation, and a hypovolemic component leading to a decrease in CBF [14-16]. At the acute phase, the presence of oxyhemoglobin in the subarachnoid spaces causes a local and systemic inflammatory reaction [17] with activation of platelets and coagulation [8-10]. The products derived from red blood cells (bilirubin) and endothelium (endothelin-1, free radicals) are considered to be mediators of the vasospasm [18-22]. Structural anomalies in endothelial and smooth muscle cells also have been reported [23].

Treatments of DCI consist of preventing or minimizing secondary injuries by means of hemodynamic managements, pharmacological agents, and endovascular procedures [12,24,25]. Although these measures result in a decrease in the incidence of vasospasm, the prognostic of DCI remain unchanged [5,24].

Because SAH is frequently accompanied by cerebral autoregulation impairment, hypotension should be avoided. To achieve an adequate cerebral perfusion pressure, triple H therapy was designed to induce volume expansion, rheology improvement, and blood pressure increase. Hence, systolic arterial pressure is

* Correspondence: Philippe.Hantson@uclouvain.be
Université catholique de Louvain (UCL), Cliniques universitaires Saint Luc,
Soins intensifs, Avenue Hippocrate, 10, B-1200 Bruxelles, Belgium

increased to approximately 150-175 mmHg once aneurysm is secured [26]. Before treating aneurysm, it is nevertheless mandatory to maintain systolic blood pressure at lower levels than 150 mmHg. However, there is now evidence suggesting that blood pressure increase is the most important part of those measures because hypervolemia does not have any benefit on cerebral blood flow and tissue oxygenation.

Although triple H therapy reverses deficits associated with vasospasm, it has not been shown to decrease DCI occurrence or mortality [27].

Besides hemodynamic treatment, various pharmacological treatments have been tested [28,29]. Nimodipine is the currently recommended drug [30]. Given its relatively modest effects, new treatments have been developed.

We review recent literature pertaining to the different drugs being used or under evaluation.

Calcium channel blockers

Nimodipine is a voltage-gated calcium channel antagonist that inhibits calcium entry into smooth muscle cells and neurons. Its lipophilic properties allow it to cross the hematoencephalic barrier. Prophylactic administration of nimodipine was shown to be efficacious in decreasing the risk of secondary ischemia and poor outcome [31,32]. The latest guidelines of the *American Stroke Association* recommend the oral administration of nimodipine at the dose of 60 mg every 4 hours for 21 days starting from the admission into the intensive care unit (Class I, Level of evidence A) [29].

The proof of its efficacy is based on four randomized, placebo-controlled trials of 853 patients, showing an improvement in functional outcome [32-36]. None of the studies were able to demonstrate a reduction in angiographic vasospasm [31]. Its benefits seem to derive from neuroprotective properties rather than its vasodilatory effects. The exact mechanism preventing and limiting the extension of ischemic lesions remains unknown. In experimental models, nimodipine has been shown to attenuate the neuronal calcium increase after cellular ischemia and causing cell death [37].

Whereas calcium is recognized to play a significant role in the occurrence of vasospasm, other elements, such as inflammatory mediators, blood rheology, or microcirculation disturbances, are to be considered. Oxyhemoglobin, for example, causes a decreased activity of potassium channels, which may lead to membrane depolarization and consecutive vasoconstriction [2].

Nimodipine has been shown to be safe [38] and cost-effective [39] without any effect on mortality. Hypotension is a rarely reported side-effect. The current recommendations are based on data pertaining to oral administration of nimodipine. A recent study attempted

to show that nimodipine's intravenous use would be associated with similar beneficial effects [40], although this mode of administration is more often linked to hypotension [41].

Among the other tested calcium channel antagonists, nicardipine was shown to decrease symptomatic vasospasm [39,42] but without having any effect on DCI and outcome. The prophylactic use of diltiazem was investigated in a single monocenter study [43]. The rate of favorable outcome was 74.8%.

During endovascular procedures, intra-arterial infusion of nicardipine [44], nimodipine [45], and diltiazem [46] were shown to reduce vasospasm with favorable effects on DCI. However, randomized control studies are still needed (Class IIb, Level of evidence B).

Lastly, two studies showed that prolonged-release nicardipine-loaded polymers implanted upon aneurysmal clipping decreased vasospasm and DCI and improved outcome [38,47]. This mode of administration is promising, although further investigations are necessary.

Tirilazad

Tirilazad mesylate is a neuroprotective corticosteroid whose efficacy was demonstrated in animal stroke models [48]. It has antioxidant properties that block free radical-induced peroxidation of membrane lipids, which has been shown to facilitate vasospasm. The compound was evaluated in combination with nimodipine in five randomized, double-blind, placebo-controlled trials on a total of 3,821 patients, but no benefit was noted on DCI or outcome [49-52]. Therefore, this drug is not recommended.

Statins

Statins are inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A, responsible for cholesterol synthesis [53]. In addition, statins display pleiotropic effects, such as anti-inflammatory effects, a stabilizing effect on atherosclerotic plaques, and anti-adhesive effects on endothelium. Neuroprotective activity also was reported [54,55].

Animal experiments showed a lower incidence of vasospasm when simvastatin therapy was initiated at the time of SAH [56,57]. This beneficial effect is assumed to be due to increased nitric oxide (NO) production on account of NO synthesis induction [58], with subsequent vasodilatation likely to improve CBF.

Several retrospective studies demonstrated that patients treated with statins before SAH presented less DCI and fewer cerebral infarctions [59]. Conversely, other retrospective investigations did not reveal any statin-induced benefits on vasospasm and outcome [60].

Two prospective phase II studies with 80 and 39 patients treated by simvastatin and pravastatin, respectively, revealed a reduction in vasospasm, a decrease in

DCI, and an improvement in functional outcome [61,62]. The use of statins deemed safe in both studies.

Nevertheless, the subsequent studies were not able to confirm the benefits of statin therapy. Two prospective, placebo-controlled trials using simvastatin on a small number of patients in addition [63,64] to three observational studies with a historic control revealed no improvement in vasospasm incidence, DCI, or outcome [59,60,65].

Even if the most recent meta-analysis did not confirm the significant effect of statins [66], it should be noted that the trial results are difficult to interpret given the variable disease severity in the control groups and the differing methodologies used. Moreover, it is hazardous to draw conclusions on the basis of four placebo-controlled trials that included only 190 patients. The potential advantage of statins cannot be ruled out. In light of their potential benefits, the current recommendations [29] state that statins may be initiated in patients with SAH (Class IIb, Level of evidence B).

Presently ongoing is a multicenter phase III study on 1,600 SAH patients: STASH (Simvastatin in Aneurysmal Subarachnoid Hemorrhage). This investigation was designed to assess the effects of simvastatin given at a 40-mg dose for 21 days versus placebo. The primary evaluation criterion is functional outcome at 6 months using the modified Rankin disability score (mRS).

Magnesium sulfate

Magnesium exerts vasodilatory effects by blocking voltage-gated calcium channels. Hypomagnesemia occurs in 38% of SAH patients and is a predictor of DCI [67].

Based on animal experimental models supporting its neuroprotective activity [68], magnesium could be instrumental in improving vasospasm and limiting cerebral ischemia in humans. Although clinical studies have demonstrated that magnesium is safe, they were not able to confirm its efficacy clearly. The first clinical trials showed a trend toward reduced DCI and improved outcome [69]. The randomized, double-blind, placebo-controlled MASH (Magnesium in Aneurysmal Subarachnoid Hemorrhage) study, including 283 patients revealed reduced DCI and improved outcome at 3 months, but the differences with placebo did not reach statistical significance [70]. Another study using the same design and involving 60 patients showed a significant reduction in vasospasm duration assessed by ultrasounds, but no difference in outcome at 6 months [71].

Given that few studies obtained sufficient statistical strength, further clinical trials continue to be undertaken. The multicentre IMASH (Intravenous Magnesium Sulphate for Aneurysmal Subarachnoid Haemorrhage) study reevaluated the effect of magnesium on 327

patients using a prospective, double-blind, placebo-controlled design. No difference in outcome was observed at 6 months, nor was there any effect on clinical vasospasm [72]. The results from another large multicenter study (MASH-II) are expected soon. Even though a few studies reported the occurrence of hypotension, data concerning its impact on DCI and outcome is still lacking [73].

Although magnesium cannot be explicitly recommended at present, it may exert neuroprotective activity, independently from the occurrence of vasospasm. In fact, the concept of predicting DCI in relation to the occurrence of vasospasm must be put into perspective. Given that endothelial dysfunction is the cause of cerebral perfusion problems, magnesium may play an important role, independently from its vasodilatory effects, although its mechanism is not yet understood. It has been shown to be protective in other types of brain injury, such as acute ischemic stroke [74].

Endothelin-1 antagonist

Endothelin (ET) is a powerful vasoconstrictor [75]. Its receptors are situated on smooth muscle cells (ET receptor ET_A and ET_{B2}) and endothelium (ET receptor ET_{B1}). The isoform 1 (ET-1) displays a more significant effect on cerebral arteries, and elevated ET-1 levels were observed in plasma and CSF (cerebrospinal fluid) after SAH [76]. ET-1 has been suggested to largely contribute to vasoconstriction-vasodilatation imbalance during SAH [77,78].

ET-1 receptor blockers have been developed and successfully tested in animals [79]. The first nonselective antagonist (TAK-044) was evaluated, showing a decrease in ischemic events at 3 months in 420 patients [80]. A selective ET_A antagonist (clazosentan) was shown to decrease the frequency and severity of vasospasm in a preliminary phase IIa study [81]. Three doses of clazosentan were recently tested on 413 patients in a randomized, double-blind, placebo-controlled study (CONSCIOUS-1: Clazosentan to Overcome Neurological Ischemia and Infarction Occurring after Subarachnoid Haemorrhage) [82]. The treatment was initiated within the first 56 hours and continued for 14 days. The aneurysmal treatment was conducted before or in the first 12 hours after administering clazosentan.

A dose-dependent decrease in angiographic vasospasm was observed. No benefit was noted on outcome, although this was not the primary evaluation criterion of the study. In post-hoc analyses, a trend toward improved clinical outcome was reported. Clazosentan was associated with an increased frequency of side-effects, such as hypotension, anaemia, and pulmonary infections. In addition, an increase in mortality was found in the active-treatment group. The majority of

deaths were due to perioperative complications. Two phase III studies (CONSCIOUS-2 and CONSCIOUS-3) are currently ongoing in patients treated using clipping or coiling [83].

Fasudil

Fasudil is a rho-kinase inhibitor, an enzyme involved in the contraction of smooth muscle cells [84]. The inhibition of the rho-kinase pathway causes cellular relaxation. Fasudil, initially investigated in Japan on 276 patients, was shown to reduce vasospasm but without any effect on outcome [85]. However, when administered intra-arterially in combination with the drainage of intracisternal clots and intracisternal urokinase injection, fasudil appeared to reduce the incidence of vasospasm and improve outcome. A recent review of 90 cases seemed to indicate that this procedure was safe and effective on vasospasm and DCI [86]. Further investigations are therefore necessary.

Antiplatelet therapy

Due to the formation of microthrombi and secretion of thromboxane A₂, platelet aggregation may play a role in DCI. Seven randomized and controlled trials involving 1,385 patients tested the effect of antiplatelet agents (acetylsalicylic acid or ticlopidine). However, none revealed any benefit on DCI or patient outcomes [87].

Enoxaparin

A single study tested the effect of low-molecular-weight heparin following SAH. In a randomized, double-blind, single-center trial of 170 patients, enoxaparin was administered 24 hours after aneurysm treatment and continued for 10 days. There was no benefit on outcome at 3 months [88]. In addition, cerebral bleeding rate was increased with enoxaparin.

Albumin

The neuroprotective activity of albumin was suggested in different types of brain injury, such as cranial trauma, cerebral ischemia, and SAH [89]. Albumin demonstrated improved CBF in a dog model of SAH [90]. Human data suggest that albumin has protective effects in ischemic stroke [91].

A retrospective study comparing albumin 25% and 0.9% NaCl administered for intravascular filling revealed improved outcome at 3 months in the albumin-treated group, whereas the incidence of vasospasm did not differ [92]. A prospective, multicenter study, Albumin in Subarachnoid Haemorrhage (ALISAH), designed to demonstrate the tolerability and safety of four doses of albumin is currently in progress [93]. This study has been designed to determine the maximally tolerated dose without provoking cardiac decompensation and

pulmonary edema. An evaluation of neurological deteriorations is performed at 15 days and 3 months. The toxin-scavenging action of albumin has already been described in numerous diseases [94]. It is possible that albumin acts by scavenging mediators of endothelial dysfunction, such as free radicals.

Nitric oxide donors

An alteration in NO production is an important mechanism in vasospasm etiology [95,96]. A decrease in NO synthesis during SAH has been noted and is responsible for deficient vessel relaxation and a subsequent decline in CBF [97]. The concept of NO donors was proposed as treatment for refractory vasospasm. Different modes of administration were tested: intravenous, intra-arterial, and intrathecal [2,98]. Intraventricular administration of sodium nitroprusside was shown to improve vasospasm and CBF, although side-effects were common [99]. One study suggested an improvement in outcome [100], whereas another involving a small number of patients did not reveal any effect of transdermal nitroglycerin [101]. Currently, NO donors have a limited place in DCI treatment, and further investigations are needed.

Erythropoietin

Erythropoietin (EPO) is an amino acid sialoglycoprotein secreted by the kidney and known to play a role in hematopoiesis [102]. EPO receptors have been found in a large number of tissues other than bone marrow, and its neuroprotective role has been suggested [103]. *In vitro* experiments and animal studies showed that EPO enhances neuronal survival under stress situations, such as excitotoxicity [104] and ischemia [105,106]. EPO doses must be sufficiently high due to its weak capacity to cross the blood-brain barrier [107]. The proposed mechanisms are diverse, including anti-inflammatory and anti-apoptotic roles, and modulating NO production [108].

Two double-blind placebo-controlled trials were conducted involving 73 and 80 patients, respectively [109,110]. Tseng et al. showed that patients treated with EPO had a lower incidence of severe vasospasm (27.5 vs. 7.5%), reduced DCI (40 vs. 7.5%), and improved outcome [105]. Even if the number of investigated patients is still low, EPO is considered to be a promising molecule given its beneficial effects at the acute SAH phase and its protective effects at the ischemic phase.

Intracisternal thrombolytics

An etiological role was attributed to spasmogenic substances released from clots in the subarachnoid spaces. Of note is that the quantity of blood is considered to be a predictor of vasospasm [111]. The intraventricular

injection of thrombolytic agents was proposed as treatment. To date, two types of thrombolytics have been tested: urokinase and t-PA (tissue plasminogen activator). The analysis of reported cases suggests a beneficial effect, although it is limited due to the small number of randomized studies [112]. Only one double-blind, placebo-controlled trial assessed the peroperative administration of t-PA on 100 patients [113]. No clear benefit was found with respect to vasospasm and DCI; only patients showing large clots experienced a decrease in vasospasm. The use of this technique requires further prospective studies to define optimal timing, mode of administration, and the type of patients likely to benefit the most. The low incidence of reported complications encourages the undertaking of new studies.

Conclusions

The poor prognosis of patients with DCI following SAH remains a major issue responsible for death and infirmity. Although our understanding of the physiopathology of DCI and vasospasm has improved, patient outcome has not been significantly modified. Management currently focuses on CBF improvement along with hemodynamic manipulation and endovascular procedures. The only recommended pharmacological treatment is nimodipine.

Although the different compounds tested mostly show a decline in the incidence of radiographic vasospasm, they do not impact on outcome. New pharmacological treatments with neuroprotective effects, such as statins, magnesium, and endothelin inhibitors, revealed promising results. However, the lack of randomized designs and insufficient statistical power of these studies do not allow us to recommend these medications in SAH management at the present time.

The disassociation of vasospasm and clinical outcome also is linked to the fact that DCI occurring after SAH is a multifactorial process without being restricted to arterial narrowing. Effectively, DCI may not only be predicted by cerebral vessels caliber alone; it also may occur in the absence of major vasospasm.

Future investigations should allow us to better understand the mechanisms of endothelial dysfunction, such as oxidative stress, inhibition of vasodilation, and the secretion of vasoconstrictors. The physiopathology of microcirculation dysfunction is all the more complex as unspecific phenomena, such as inflammation, platelet activation, and microthrombi formation. In addition, vasoconstrictors, such as norepinephrine, may have paradoxical effects, and their impact on cerebral microcirculation has not been determined yet.

There is evidence supporting the use of neuroprotective agents. The results of ongoing randomized studies will confirm or not the efficacy of these new

treatments. While awaiting potential benefits from neuroprotective treatments, the standard management of intensive care patients using specifically metabolic and ionic control as well as temperature maintenance is still required to preserve the damaged brain. Fever is a common complication and is related to prognosis during the first 2 weeks after SAH [114]. If hyperthermia should be avoided in a patient with increased intracranial pressure, early fever control after SAH could be associated with improved outcome. Recent retrospective data have shown that temperature maintenance above 37°C during the first 2 weeks may be associated with a better outcome [115].

Authors' contributions

DCZ and PH wrote the present manuscript and approved its final version.

Competing interests

The authors declare that they have no competing interests.

Received: 25 March 2011 Accepted: 24 May 2011

Published: 24 May 2011

References

1. de Rooij NK, Linn FH, van der Plas JA, Algra A, Rinkel GJ: **Incidence of subarachnoid haemorrhage: a systematic review with emphasis on region, age, gender and time trends.** *J Neurol Neurosurg Psychiatry* 2007, **78**:1365-1372.
2. Pluta RM, Hansen-Schwartz J, Dreier J, Vajkoczy P, Macdonald RL, Nishizawa S, Kasuya H, Wellman G, Keller E, Zauner A, Dorsch N, Clark J, Ono S, Kiris T, Leroux P, Zhang JH: **Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought.** *Neurol Res* 2009, **31**:151-158.
3. Ferguson S, Macdonald RL: **Predictors of cerebral infarction in patients with aneurysmal subarachnoid hemorrhage.** *Neurosurgery* 2007, **60**:658-667.
4. Dorsch NW, King MT: **A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I: Incidence and effects.** *J Clin Neurosci* 1994, **1**:19-26.
5. Rabinstein AA, Friedman JA, Weigand SD, McClelland RL, Fulgham JR, Manno EM, Atkinson JL, Wijidicks EF: **Predictors of cerebral infarction in aneurysmal subarachnoid hemorrhage.** *Stroke* 2004, **35**:1862-1866.
6. Macdonald RL, Pluta RM, Zhang JH: **Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution.** *Nat Clin Pract Neurol* 2007, **3**:256-263.
7. Vajkoczy P, Horn P, Thome C, Munch E, Schmiedek P: **Regional cerebral blood flow monitoring in the diagnosis of delayed ischemia following aneurysmal subarachnoid hemorrhage.** *J Neurosurg* 2003, **98**:1227-1234.
8. Heros RC, Zervas NT, Varsos V: **Cerebral vasospasm after subarachnoid hemorrhage: an update.** *Ann Neurol* 1983, **14**:599-608.
9. Fisher CM, Roberson GH, Ojemann RG: **Cerebral vasospasm with ruptured saccular aneurysm—the clinical manifestations.** *Neurosurgery* 1977, **1**:245-248.
10. Kassell NF, Sasaki T, Colohan AR, Nazar G: **Cerebral vasospasm following aneurysmal subarachnoid hemorrhage.** *Stroke* 1985, **16**:562-572.
11. Greenberg ED, Gold R, Reichman M, John M, Ivanidze J, Edwards AM, Johnson CE, Comunale JP, Sanelli P: **Diagnostic accuracy of CT angiography and CT perfusion for cerebral vasospasm: a meta-analysis.** *Am J Neuroradiol* 2010, **31**:1853-1860.
12. Weir B, Grace M, Hansen J, Rothberg C: **Time course of vasospasm in man.** *J Neurosurg* 1978, **48**:173-178.
13. Suarez JJ, Tarr RW, Selman WR: **Aneurysmal subarachnoid hemorrhage.** *N Engl J Med* 2006, **354**:387-396.
14. Dhar R, Diringner MN: **The burden of the systemic inflammatory response predicts vasospasm and outcome after subarachnoid hemorrhage.** *Neurocrit Care* 2008, **8**:404-412.

15. Diringner MN: **Subarachnoid hemorrhage: a multiple-organ system disease.** *Crit Care Med* 2003, **31**:1884-1885.
16. Dumont AS, Dumont RJ, Chow MM, Lin CL, Calisaneler T, Ley KF, Kassell NF, Lee KS: **Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation.** *Neurosurgery* 2003, **53**:123-133.
17. Yoshimoto Y, Tanaka Y, Hoya K: **Acute systemic inflammatory response syndrome in subarachnoid hemorrhage.** *Stroke* 2001, **32**:1989-1993.
18. Liszczak TM, Varsos VG, Black PM, Kistler JP, Zervas NT: **Cerebral arterial constriction after experimental subarachnoid hemorrhage is associated with blood components within the arterial wall.** *J Neurosurg* 1983, **58**:18-26.
19. Macdonald RL, Weir BK: **A review of hemoglobin and the pathogenesis of cerebral vasospasm.** *Stroke* 1991, **22**:971-982.
20. Mayberg MR, Okada T, Bark DH: **The role of hemoglobin in arterial narrowing after subarachnoid hemorrhage.** *J Neurosurg* 1990, **72**:634-640.
21. Rubanyi GM: **Endothelium-derived relaxing and contracting factors.** *J Cell Biochem* 1991, **46**:27-36.
22. Hendryk S, Jarzab B, Josko J: **Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH.** *Neuro Endocrinol Lett* 2004, **25**:141-147.
23. Peterson JW, Kwun BD, Hackett JD, Zervas NT: **The role of inflammation in experimental cerebral vasospasm.** *J Neurosurg* 1990, **72**:767-774.
24. Weyer GW, Nolan CP, Macdonald RL: **Evidence-based cerebral vasospasm management.** *Neurosurg Focus* 2006, **21**:E8.
25. Kassell NF, Torner JC, Haley EC, Jane JA, Adams HP, Kongable GL: **The International Cooperative Study on the Timing of Aneurysm Surgery. Part 1: Overall management results.** *J Neurosurg* 1990, **73**:18-36.
26. Origitano TC, Wascher TM, Reichman OH, Anderson DE: **Sustained increased cerebral blood flow with prophylactic hypertensive hypervolemic hemodilution ("triple-H" therapy) after subarachnoid hemorrhage.** *Neurosurgery* 1990, **27**:729-739.
27. Treggiari MM, Walder B, Suter PM, Romand JA: **Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage.** *J Neurosurg* 2003, **98**:978-984.
28. Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL: **Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis.** *J Cereb Blood Flow Metab* .
29. Rabinstein AA, Lanzino G, Wijdicks EF: **Multidisciplinary management and emerging therapeutic strategies in aneurysmal subarachnoid haemorrhage.** *Lancet Neurol* 2010, **9**:504-519.
30. Bederson JB, Connolly ES, Batjer HH, Dacey RG, Dion JE, Diringner MN, Duldney JE, Harbaugh RE, Patel AB, Rosenwasser RH, American Heart Association: **Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.** *Stroke* 2009, **40**:994-1025.
31. Feigin VL, Rinkel GJ, Algra A, Vermeulen M, van Gijn J: **Calcium antagonists in patients with aneurysmal subarachnoid hemorrhage: a systematic review.** *Neurology* 1998, **50**:876-883.
32. Allen GS, Ahn HS, Preziosi TJ, Batty R, Boone SC, Chou SN, Kelly DL, Weir BK, Crabbe RA, Lavik PJ, Rosenbloom SB, Dorsey FC, Ingram CR, Mellits DE, Bertsch LA, Boisvert DP, Hundley MB, Johnson RK, Strom JA, Transou CR: **Cerebral arterial spasm-a controlled trial of nimodipine in patients with subarachnoid hemorrhage.** *N Engl J Med* 1983, **308**:619-624.
33. Philippon J, Grob R, Dagereu F, Guggiari M, Rivierez M, Vias P: **Prevention of vasospasm in subarachnoid hemorrhage. A controlled study with nimodipine.** *Acta Neurochir* 1986, **82**:110-4.
34. Mee E, Dorrance D, Lowe D, Neil-Dwyer G: **Controlled study of nimodipine in aneurysm patients treated early after subarachnoid hemorrhage.** *Neurosurgery* 1988, **22**:484-491.
35. Petruk KC, West M, Mohr G, Weir BK, Benoit BG, Gentili F, Disney LB, Khan MI, Grace M, Holness RO, Karwon MS, Ford RM, Cameron GS, Tucker WS, Purves GB, Miller JD, Hunter KM, Richard MT, Durity FA, Chan R, Clein LJ, Maroun FB, Godon A: **Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial.** *J Neurosurg* 1988, **68**:505-517.
36. Pickard JD, Murray GD, Illingworth R, Shaw MD, Teasdale GM, Foy PM, Humphrey PR, Lang DA, Nelson R, Richards P, Sinar J, Bailey S, Skene A: **Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial.** *BMJ* 1989, **298**:636-642.
37. Zornow MH, Prough DS: **Neuroprotective properties of calcium-channel blockers.** *New Horiz* 1996, **4**:107-114.
38. Kasuya H, Onda H, Takeshita M, Okada Y, Hori T: **Efficacy and safety of nicardipine prolonged-release implants for preventing vasospasm in humans.** *Stroke* 2002, **33**:1011-1015.
39. Karinen P, Koivukangas P, Ohinmaa A, Koivukangas J, Ohman J: **Cost-effectiveness analysis of nimodipine treatment after aneurysmal subarachnoid hemorrhage and surgery.** *Neurosurgery* 1999, **45**:780-784.
40. Kronvall E, Urdren P, Romner B, Saveland H, Cronqvist M, Nilsson OG: **Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration.** *J Neurosurg* 2009, **110**:58-63.
41. Haley EC, Kassell NF, Torner JC: **A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study.** *J Neurosurg* 1993, **78**:537-547.
42. Abe K, Iwanaga H, Inada E: **Effect of nicardipine and diltiazem on internal carotid artery blood flow velocity and local cerebral blood flow during cerebral aneurysm surgery for subarachnoid hemorrhage.** *J Clinl Anesth* 1994, **6**:99-105.
43. Papavasiliou AK, Harbaugh KS, Birkmeyer NJ, Feeney JM, Martin PB, Faccio C, Harbaugh RE: **Clinical outcomes of aneurysmal subarachnoid hemorrhage patients treated with oral diltiazem and limited intensive care management.** *Surg Neurol* 2001, **55**:138-146.
44. Schmidt U, Bittner E, Pivi S, Marota JJ: **Hemodynamic management and outcome of patients treated for cerebral vasospasm with intraarterial nicardipine and/or milrinone.** *Anesth Analg* 2010, **110**:895-902.
45. Hui C, Lau KP: **Efficacy of intra-arterial nimodipine in the treatment of cerebral vasospasm complicating subarachnoid haemorrhage.** *Clin Radiol* 2005, **60**:1030-1036.
46. Saunders FW, Marshall WJ: **Diltiazem: dose it affect vasospasm?** *Surg Neurol* 1986, **26**:155-158.
47. Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T: **Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid hemorrhage.** *Neurosurgery* 2005, **56**:895-902.
48. Kanamaru K, Weir BK, Findlay JM, Grace M, Macdonald RL: **A dosage study of the effect of the 21-aminosteroid U74006F on chronic cerebral vasospasm in a primate model.** *Neurosurgery* 1990, **27**:29-38.
49. Kassell NF, Haley EC, Apperson-Hansen C, Alves WM: **Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand.** *J Neurosurg* 1996, **84**:221-228.
50. Haley EC, Kassell NF, Apperson-Hansen C, Maile MH, Alves WM: **A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America.** *J Neurosurg* 1997, **86**:467-474.
51. Lanzino G, Kassell NF: **Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America.** *J Neurosurg* 1999, **90**:1018-1024.
52. Lanzino G, Kassell NF, Dorsch NW, Pasqualin A, Brandt L, Schmiedek P, Truskowski LL, Alves WM: **Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa.** *J Neurosurg* 1999, **90**:1011-1017.
53. Endo A: **The discovery and development of HMG-CoA reductase inhibitors.** *J Lipid Res* 1992, **33**:1569-1582.
54. Liao JK, Laufs U: **Pleiotropic effects of statins.** *Annu Rev Pharmacol Toxicol* 2005, **45**:89-118.
55. van der Most PJ, Dolga AM, Nijholt IM, Luiten PG, Eisel UL: **Statins: mechanisms of neuroprotection.** *Prog Neurobiol* 2009, **88**:64-75.
56. Aoki T, Kataoka H, Ishibashi R, Nozaki K, Hashimoto N: **Simvastatin suppresses the progression of experimentally induced cerebral aneurysms in rats.** *Stroke* 2008, **39**:1276-1285.
57. Bulsara KR, Coates JR, Agrawal VK, Eifler DM, Wagner-Mann CC, Durham HE, Fine DM, Toft K: **Effect of combined simvastatin and cyclosporine compared with simvastatin alone on cerebral vasospasm after**

- subarachnoid hemorrhage in a canine model. *Neurosurg Focus* 2006, **21**:E11.
58. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK: **Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.** *Proc Natl Acad Sci USA* 1998, **95**:8880-8885.
59. McGirt MJ, Blessing R, Alexander MJ, Nimjee SM, Woodworth GF, Friedman AH, Graffagnino C, Laskowitz DT, Lynch JR: **Risk of cerebral vasospasm after subarachnoid hemorrhage reduced by statin therapy: A multivariate analysis of an institutional experience.** *J Neurosurg* 2006, **105**:671-674.
60. Kern M, Lam MM, Knuckey NW, Lind CR: **Statins may not protect against vasospasm in subarachnoid haemorrhage.** *J Clin Neurosci* 2009, **16**:527-530.
61. Lynch JR, Wang H, McGirt MJ, Floyd J, Friedman AH, Coon AL, Blessing R, Alexander MJ, Graffagnino C, Warner DS, Laskowitz DT: **Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial.** *Stroke* 2005, **36**:2024-2026.
62. Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ: **Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial.** *Stroke* 2005, **36**:1627-1632.
63. Vergouwen MD, Meijers JC, Geskus RB, Coert BA, Horn J, Stroes ES, van der Poll T, Vermeulen M, Roos YB: **Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial.** *J Cereb Blood Flow Metab* 2009, **29**:1444-1453.
64. Chou SH, Smith EE, Badjatia N, Nogueira RG, Sims JR, Ogilvy CS, Rordorf GA, Ayata C: **A randomized, double-blind, placebo-controlled pilot study of simvastatin in aneurysmal subarachnoid hemorrhage.** *Stroke* 2008, **39**:2891-2893.
65. Kramer AH, Gurka MJ, Nathan B, Dumont AS, Kassell NF, Bleck TP: **Statin use was not associated with less vasospasm or improved outcome after subarachnoid hemorrhage.** *Neurosurgery* 2008, **62**:422-427.
66. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB: **Effect of statin treatment on vasospasm, delayed cerebral ischemia, and functional outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis update.** *Stroke* 2010, **41**:e47-e52.
67. van den Bergh WM, Algra A, van der Sprenkel JW, Tulleken CA, Rinkel GJ: **Hypomagnesemia after aneurysmal subarachnoid hemorrhage.** *Neurosurgery* 2003, **52**:276-281.
68. Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE: **Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia.** *J Neurosurg* 1996, **85**:117-124.
69. Veyna RS, Seyfried D, Burke DG, Zimmerman C, Mlynarek M, Nichols V, Marrocco A, Thomas AJ, Mitsias PD, Malik GM: **Magnesium sulfate therapy after aneurysmal subarachnoid hemorrhage.** *J Neurosurg* 2002, **96**:510-514.
70. van den Bergh WM, Algra A, van Kooten F, Dirven CM, van Gijn J, Vermeulen M, Marrocco A, Thomas AJ, Mitsias PD, Malik GM: **Magnesium sulfate in aneurysmal subarachnoid hemorrhage: a randomized controlled trial.** *Stroke* 2005, **36**:1011-1015.
71. Wong GK, Chan MT, Boet R, Poon WS, Gin T: **Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: a prospective randomized pilot study.** *J Neurosurg Anesthesiol* 2006, **18**:142-148.
72. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, Zee BC, IMASH Investigators: **Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial.** *Stroke* 2010, **41**:921-926.
73. Wong GK, Chan MT, Gin T, Poon WS: **Intravenous magnesium sulfate after aneurysmal subarachnoid hemorrhage: current status.** *Acta Neurochir* 2011, **110**(Suppl):169-173.
74. Saver JL: **Target brain: neuroprotection and neurorestoration in ischemic stroke.** *Rev Neurol Dis* 2010, **7**(Suppl 1):14-21.
75. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T: **A novel potent vasoconstrictor peptide produced by vascular endothelial cells.** *Nature* 1988, **332**:411-415.
76. Pluta RM, Boock RJ, Afshar JK, Clouse K, Bacic M, Ehrenreich H, Oldfield EH: **Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage.** *J Neurosurg* 1997, **87**:287-293.
77. Zimmermann M, Seifert V: **Endothelin and subarachnoid hemorrhage: an overview.** *Neurosurgery* 1998, **43**:863-75.
78. Zimmermann M, Seifert V: **Endothelin receptor antagonists and cerebral vasospasm.** *Clin Auton Res* 2004, **14**:143-145.
79. Hansen-Schwartz J, Hoel NL, Zhou M, Xu CB, Svendgaard NA, Edvinsson L: **Subarachnoid hemorrhage enhances endothelin receptor expression and function in rat cerebral arteries.** *Neurosurgery* 2003, **52**:1188-1194.
80. Shaw MD, Vermeulen M, Murray GD, Pickard JD, Bell BA, Teasdale GM: **Efficacy and safety of the endothelin, receptor antagonist TAK-044 in treating subarachnoid hemorrhage: a report by the Steering Committee on behalf of the UK/Netherlands/Eire TAK-044 Subarachnoid Haemorrhage Study Group.** *J Neurosurg* 2000, **93**:992-997.
81. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P: **Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study.** *J Neurosurg* 2005, **103**:9-17.
82. Macdonald RL, Kassell NF, Mayer S, Ruefenacht D, Schmiedek P, Weidauer S, Frey A, Roux S, Pasqualin A, CONSCIOUS-1 Investigators: **Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.** *Stroke* 2008, **39**:3015-3021.
83. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Frey A, Marr A, Roux S, Kassell NF: **Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials.** *Neurocrit Care* 2010, **13**:416-424.
84. Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P, Loirand G: **Cyclic GMP-dependent protein kinase signaling pathway inhibits RhoA-induced Ca²⁺ sensitization of contraction in vascular smooth muscle.** *J Biol Chem* 2000, **275**:21722-21729.
85. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, Hidaka H, Mitsuoyoshi Nakashima: **Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial.** *J Neurosurg* 1992, **76**:571-577.
86. Iwabuchi S, Yokouchi T, Hayashi M, Sato K, Saito N, Hirata Y, Harashina J, Nakayama H, Akahata M, Ito K, Kimura H, Aoki K: **Intra-arterial Administration of Fasudil Hydrochloride for Vasospasm Following Subarachnoid Haemorrhage: Experience of 90 Cases.** *Acta Neurochir* 2011, **110**(Suppl):179-181.
87. Dorhout Mees SM, van den Bergh WM, Algra A, Rinkel GJ: **Antiplatelet therapy for aneurysmal subarachnoid haemorrhage.** *Cochrane database of systematic reviews* 2007, **4**:CD006184.
88. Siironen J, Juvela S, Varis J, Porras M, Poussa K, Ilveskero S, Hernesniemi J, Lassila R: **No effect of enoxaparin on outcome of aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled clinical trial.** *J Neurosurg* 2003, **99**:953-959.
89. Belayev L, Saul I, Huh PW, Finotti N, Zhao W, Busto R, Ginsberg MD: **Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats.** *Brain Res* 1999, **845**:107-111.
90. Matsui T, Asano T: **The hemodynamic effects of prolonged albumin administration in beagle dogs exposed to experimental subarachnoid hemorrhage.** *Neurosurgery* 1993, **32**:79-83.
91. Ginsberg MD, Hill MD, Palesch YY, Ryckborst KJ, Tamariz D: **The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke—I: Physiological responses and safety results.** *Stroke* 2006, **37**:2100-2106.
92. Suarez JJ, Shannon L, Zaidat OO, Suri MF, Singh G, Lynch G, Selman WR: **Effect of human albumin administration on clinical outcome and hospital cost in patients with subarachnoid hemorrhage.** *J Neurosurg* 2004, **100**:585-590.
93. Suarez JJ, Martin RH: **Treatment of subarachnoid hemorrhage with human albumin: ALISAH study. Rationale and design.** *Neurocrit Care* 2010, **13**:263-277.
94. Boldt J: **Use of albumin: an update.** *Br J Anaesth* 2010, **104**:276-84.
95. Faraci FM: **Role of endothelium-derived relaxing factor in cerebral circulation: large arteries vs. microcirculation.** *Am J Physiol* 1991, **261**:H1038-1042.

96. Pluta RM, Thompson BG, Afshar JK, Boock RJ, Iuliano B, Oldfield EH: **Nitric oxide and vasospasm.** *Acta Neurochir* 2001, **77**(Suppl):67-72.
97. Pluta RM: **Delayed cerebral vasospasm and nitric oxide: review, new hypothesis, and proposed treatment.** *Pharmacol Ther* 2005, **105**:23-56.
98. Keyrouz SG, Diringer MN: **Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage.** *Critical care* 2007, **11**:220.
99. Thomas JE, Rosenwasser RH: **Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: initial observations regarding the use of intraventricular sodium nitroprusside in humans.** *Neurosurgery* 1999, **44**:48-57.
100. Agrawal A, Patir R, Kato Y, Chopra S, Sano H, Kanno T: **Role of intraventricular sodium nitroprusside in vasospasm secondary to aneurysmal subarachnoid haemorrhage: a 5-year prospective study with review of the literature.** *Minim Invasive Neurosurg* 2009, **52**:5-8.
101. Reinert M, Wiest R, Barth L, Andres R, Ozdoba C, Seiler R: **Transdermal nitroglycerin in patients with subarachnoid hemorrhage.** *Neurol Res* 2004, **26**:435-439.
102. Fisher JW: **Erythropoietin: physiology and pharmacology update.** *Exp Biol Med* 2003, **228**:1-14.
103. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, Brines M, Ghezzi P: **Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis.** *J Exp Med* 2003, **198**:971-975.
104. Koshimura K, Murakami Y, Sohmiya M, Tanaka J, Kato Y: **Effects of erythropoietin on neuronal activity.** *J Neurochem* 1999, **72**:2565-2572.
105. Celik M, Gokmen N, Erbayraktar S, Akhisaroglu M, Konakc S, Ulukus C, Genc S, Genc K, Sagiroglu E, Cerami A, Brines M: **Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury.** *Proc Natl Acad Sci USA* 2002, **99**:2258-2263.
106. Kumral A, Ozer E, Yilmaz O, Akhisaroglu M, Gokmen N, Duman N, Ulukus C, Genc S, Ozkan H: **Neuroprotective effect of erythropoietin on hypoxic-ischemic brain injury in neonatal rats.** *Biol neonate* 2003, **83**:224-228.
107. Brines ML, Ghezzi P, Keenan S, Agnello D, de Lanerolle NC, Cerami C, Itri LM, Cerami A: **Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.** *Proc Natl Acad Sci USA* 2000, **97**:10526-10531.
108. Arcasoy MO: **The non-haematopoietic biological effects of erythropoietin.** *Br J Haematol* 2008, **141**:14-31.
109. Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ: **Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial.** *J Neurosurg* 2009, **111**:171-180.
110. Springborg JB, Moller C, Gideon P, Jorgensen OS, Juhler M, Olsen NV: **Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial.** *Acta Neurochir* 2007, **149**:1089-1101.
111. Fisher CM, Kistler JP, Davis JM: **Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning.** *Neurosurgery* 1980, **6**:1-9.
112. Amin-Hanjani S, Ogilvy CS, Barker FG: **Does intracisternal thrombolysis prevent vasospasm after aneurysmal subarachnoid hemorrhage? A meta-analysis.** *Neurosurgery* 2004, **54**:326-334.
113. Findlay JM, Kassell NF, Weir BK, Haley EC, Kongable G, Germanson T, Truskowski L, Alves WM, Holness RO, Knuckey NW, Yonas H, Steinberg G, West M, Winn HR, Ferguson G: **A randomized trial of intraoperative, intracisternal tissue plasminogen activator for the prevention of vasospasm.** *Neurosurgery* 1995, **37**:168-176.
114. Oliveira-Filho J, Ezzeddine MA, Segal AZ, Buonanno FS, Chang Y, Ogilvy CS, Rordorf G, Schwamm LH, Koroshetz WJ, McDonald CT: **Fever in subarachnoid hemorrhage: relationship to vasospasm and outcome.** *Neurology* 2001, **56**:1299-1304.
115. Badjatia N, Fernandez L, Schmidt JM, Lee K, Claassen J, Connolly ES, Mayer SA: **Impact of induced normothermia on outcome after subarachnoid hemorrhage: a case-control study.** *Neurosurgery* 2010, **66**:696-700.

doi:10.1186/2110-5820-1-12

Cite this article as: Castanares-Zapatero and Hantson: Pharmacological treatment of delayed cerebral ischemia and vasospasm in subarachnoid hemorrhage. *Annals of Intensive Care* 2011 **1**:12.

Submit your manuscript to a SpringerOpen® journal and benefit from:

- Convenient online submission
- Rigorous peer review
- Immediate publication on acceptance
- Open access: articles freely available online
- High visibility within the field
- Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com
